机构地区:[1]BGI,Shenzhen,China [2]BGI Research,Shenzhen,China [3]Department of Pharmacy,School of Health Sciences,University of Patras,Patras,Greece [4]Center for Evolutionary Biology,School of Life Sciences,Fudan University,Shanghai,China [5]Department of Population Medicine,M.Kandiah Faculty of Medicine and Health Sciences,Universiti Tunku Abdul Rahman,Selangor,Malaysia [6]Genetic&Metabolism Unit,Department of Paediatrics,Faculty of Medicine,University of Malaya,Kuala Lumpur,Malaysia [7]Clinical Trial Service Unit&Epidemiological Studies Unit,Nuffield Department of Population Health,University of Oxford,Oxford,UK [8]CODATA International Data Policy Committee(IDPC)and Strategic Initiative for Developing Capacity in Ethical Review-Europe(SIDCER),Leuven,Belgium [9]Department of Epidemiology&Biostatistics,School of Public Health,Peking University,Beijing,China [10]Peking University Center for Public Health and Epidemic Preparedness&Response,Beijing,China [11]Key Laboratory of Epidemiology of Major Diseases(Peking University),Ministry of Education,Beijing,China [12]Department of History of Medicine and Ethics Bioethics/WMA Cooperation Center,School of Medicine,TOBB University of Economics and Technology,and CODATA International Data Policy Committee,Ankara,Turkey [13]MGI,San Jose,CA,USA [14]Provost Office,Singapore Management University,Singapore,Singapore [15]Department of Gastroenterology and Digestive Oncology,AP-HP Avicenne Hospital,Sorbonne Paris Nord University,Bobigny,France [16]Hanoi Medical University,Hanoi,Vietnam [17]University of Queensland,Queensland,Australia [18]Genome Engineering Laboratory,Moscow Institute of Physics and Technology,Dolgoprudniy,Russian Federation [19]Australian Institute of Tropical Health and Medicine,James Cook University,Smithfield,QLD,Australia [20]Human Technopole,Milan,Italy [21]RIKEN Center for Integrative Medical Sciences,Yokohama,Japan [22]John C.Martin Centre for Liver Research and Innovations,Kolkata,India [23]Department of Genetics,Harvard Medical School,Boston,MA,USA
出 处:《Cell Research》2024年第11期747-750,共4页细胞研究(英文版)
摘 要:Upon announcing the completion of the Human Genome Project(HGP)in 2003,scientific leaders envisaged the transformative promise of the human genome for health and society.1 They anticipated genomics breakthroughs that could touch all of humanity and empower people to have longer healthier lives,ultimately creating a more prosperous society that also wields the human genome responsibly.Two decades on,human genomics now underpins the prospects of precision medicine and precision public health(Box 1).However,as further impactful advances increasingly depend on world-wide representation and collabora-tion,global-scale challenges that shackle progress must now be addressed.These are mainly economic,organizational,infrastruc-tural,scientific,and Ethical,Legal and Social Implications(ELSI)challenges.Existing efforts lack coordination at the scale and scope required to overcome these challenges.In a time of heightened geopolitical uncertainty and legitimate citizen con-cern over the conscientious use of data and data-analysis methodologies,which include genomics big data and artificial intelligence(AI),we must draw inspiration from precedents where bold goals organized humanity to responsibly employ the best technologies and collaborative science toward their solution.2 In an era where intense corporate competition and geopolitical agendas threaten global collaboration,we must galvanize efforts to make precision medicine a universal gift—available and accessible to all of humanity for the generations to come.
关 键 词:BREAKTHROUGH HUMANITY OVERCOME
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...